▲ Peaking
Business
Novartis to Buy Myricx Bio for Up to $1.5 Billion
Novartis is expanding its cancer-drug pipeline through the acquisition of UK-based biotech firm Myricx Bio in a deal valued up to $1.5 billion.
ADC
1 news trends Newsylist has tracked involving ADC — newest first.